User login
Key clinical point: The addition of atezolizumab to chemotherapy with nanoparticle albumin-bound nab-paclitaxel and carboplatin failed to improve pathological complete response (pCR) rates compared with chemotherapy alone in early high-risk, locally advanced, triple-negative breast cancer (TNBC).
Major finding: The rate of pCR was not significantly different between atezolizumab and non-atezolizumab treatment arms (48.6% vs. 44.4%; odds ratio 1.18; P = .48). Serious adverse events and any grade liver transaminase abnormalities were higher in the atezolizumab vs. non-atezolizumab treatment arm (P = .001).
Study details: Findings are from the NeoTRIP study including 280 women with early high-risk, locally advanced TNBC who were randomly assigned to receive neoadjuvant carboplatin and nab-paclitaxel with or without atezolizumab.
Disclosures: This study was supported by Fondazione Michelangelo. The authors declared serving on advisory boards or receiving consulting fees, honoraria, grants, support for attending meetings, and other nonfinancial support from several sources.
Source: Gianni L et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022 (Feb 16). Doi: 10.1016/j.annonc.2022.02.004
Key clinical point: The addition of atezolizumab to chemotherapy with nanoparticle albumin-bound nab-paclitaxel and carboplatin failed to improve pathological complete response (pCR) rates compared with chemotherapy alone in early high-risk, locally advanced, triple-negative breast cancer (TNBC).
Major finding: The rate of pCR was not significantly different between atezolizumab and non-atezolizumab treatment arms (48.6% vs. 44.4%; odds ratio 1.18; P = .48). Serious adverse events and any grade liver transaminase abnormalities were higher in the atezolizumab vs. non-atezolizumab treatment arm (P = .001).
Study details: Findings are from the NeoTRIP study including 280 women with early high-risk, locally advanced TNBC who were randomly assigned to receive neoadjuvant carboplatin and nab-paclitaxel with or without atezolizumab.
Disclosures: This study was supported by Fondazione Michelangelo. The authors declared serving on advisory boards or receiving consulting fees, honoraria, grants, support for attending meetings, and other nonfinancial support from several sources.
Source: Gianni L et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022 (Feb 16). Doi: 10.1016/j.annonc.2022.02.004
Key clinical point: The addition of atezolizumab to chemotherapy with nanoparticle albumin-bound nab-paclitaxel and carboplatin failed to improve pathological complete response (pCR) rates compared with chemotherapy alone in early high-risk, locally advanced, triple-negative breast cancer (TNBC).
Major finding: The rate of pCR was not significantly different between atezolizumab and non-atezolizumab treatment arms (48.6% vs. 44.4%; odds ratio 1.18; P = .48). Serious adverse events and any grade liver transaminase abnormalities were higher in the atezolizumab vs. non-atezolizumab treatment arm (P = .001).
Study details: Findings are from the NeoTRIP study including 280 women with early high-risk, locally advanced TNBC who were randomly assigned to receive neoadjuvant carboplatin and nab-paclitaxel with or without atezolizumab.
Disclosures: This study was supported by Fondazione Michelangelo. The authors declared serving on advisory boards or receiving consulting fees, honoraria, grants, support for attending meetings, and other nonfinancial support from several sources.
Source: Gianni L et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022 (Feb 16). Doi: 10.1016/j.annonc.2022.02.004